Sunshine Biopharma Inc
SBFM1.470USD
+0.060+4.25%
Market hours （ET）Quotes delayed by 15 min
3.98MMarket Cap
LossP/E TTM
More Details of Sunshine Biopharma Inc Company
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Company Info
Ticker SymbolSBFM
Company nameSunshine Biopharma Inc
IPO dateAug 15, 2008
CEODr. Steve N. Slilaty
Number of employees52
Security typeOrdinary Share
Fiscal year-endAug 15
Address333 Las Olas Way
CityFORT LAUDERDALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33301
Phone19543300684
Websitehttps://www.sunshinebiopharma.com/
Ticker SymbolSBFM
IPO dateAug 15, 2008
CEODr. Steve N. Slilaty
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
1.85K
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
1.85K
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
3.12%
Altium Capital Management LP
1.11%
UBS Financial Services, Inc.
0.44%
SBI Securities Co., Ltd.
0.11%
Morgan Stanley Smith Barney LLC
0.08%
Other
95.13%
Shareholders
Shareholders
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
3.12%
Altium Capital Management LP
1.11%
UBS Financial Services, Inc.
0.44%
SBI Securities Co., Ltd.
0.11%
Morgan Stanley Smith Barney LLC
0.08%
Other
95.13%
Shareholder Types
Shareholders
Proportion
Corporation
3.12%
Investment Advisor/Hedge Fund
1.11%
Investment Advisor
0.52%
Research Firm
0.11%
Individual Investor
0.05%
Other
95.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
40
223.70K
4.91%
-115.64K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
2023Q2
34
3.32K
29.59%
+626.00
2023Q1
34
2.26K
20.01%
-741.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
L1 Capital Global Opportunities Master Fund Ltd.
142.24K
3.12%
+139.60K
+5281.91%
Dec 31, 2024
Altium Capital Management LP
50.47K
1.11%
+48.60K
+2607.40%
Mar 31, 2025
UBS Financial Services, Inc.
19.89K
0.44%
+19.02K
+2190.90%
Mar 31, 2025
SBI Securities Co., Ltd.
5.22K
0.11%
+4.51K
+636.67%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Mar 31, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Apr 01, 2025
Slilaty (Steve N)
61.00
0%
--
--
Apr 01, 2025
Sebaaly (Camille)
60.00
0%
--
--
Apr 01, 2025
Merzouki (Abderrazzak)
59.00
0%
--
--
Apr 01, 2025
National Bank of Canada
10.00
0%
+3.00
+42.86%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Date
Type
Ratio
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
